Amgen’s investigational AMG 416 succeeded in its final late-stage study for secondary hyperparathyroidism in patients with chronic kidney disease. The company announced results from the head-to-head Phase III study comparing AMG 416 with its in-house rival Sensipar (cinacalcet) for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney …